CommercialPrior AuthMedium impact
Alglucosidase Alfa (Lumizyme®)
BCBS Tennessee·TN · Genetics, Pediatrics, Internal Medicine·Medical Policy
Effective date
Dec 1, 2026
We identified it
Sep 10, 2026
Summary
BlueCross BlueShield of Tennessee is establishing a new medical policy for Alglucosidase Alfa (Lumizyme®) for treatment of Pompe disease. The policy requires prior authorization with specific diagnostic confirmation (enzyme assay or genetic testing), clinical documentation of disease symptoms, and prescriber specialization in metabolic/lysosomal storage disorders. Coverage is limited to FDA-approved indications for Pompe disease; all other uses are considered experimental/investigational.
Action Required
By November 15, 2026: Billing team must implement prior authorization workflows for Lumizyme claims. (1) Update billing system to require prior auth for all Alglucosidase Alfa prescriptions. (2) Create prior auth checklist requiring: enzyme assay results (<1% normal for infantile-onset, <40% for late-onset Pompe Disease) OR genetic testing confirming Pompe disease diagnosis, and clinical documentation of baseline disease symptoms (progressive proximal muscle weakness, respiratory insufficiency, cardiomyopathy) for late-onset cases. (3) Verify prescriber credentials to confirm specialization in metabolic disease and/or lysosomal storage disorders before processing claims. (4) For reauthorization requests after 12 months, require documentation of therapy response (improvement, stabilization, disease progression slowing, functional capacity changes, or LVMI reduction). (5) Update provider communications and encounter templates to notify prescribers of documentation and specialization requirements. (6) Train front desk and prior auth staff on new requirements. Claims submitted without proper prior authorization and supporting documentation will be denied.